Sirtex Cover.proof 11 - School of Educators

More documents

Recommendations

Info

2 Section Key Dates and General Information Key Dates Application list opens Tuesday 25 July 2000 Application list closes Friday 11 August 2000 Expected date of dispatch of holding statements Thursday 17 August 2000 Expected date of quotation of Shares on the ASX Thursday 24 August 2000 Offer Statistics Offer Price $1.00 Number of Shares on issue following the Offer 54,000,000 Number of Shares being offered by this Prospectus 15,000,000 Gross proceeds from issue available to Sirtex Medical $15 million Market Capitalisation at the Offer Price $54 million Net assets per Share 34.6 cents (note 1) Net tangible assets per Share 28.8 cents (note 1) Notes 1. Based on the pro forma balance sheet (refer Section 3).
Section 2 1 The incidence of cancer is increasing as advances in medical science lead to a decrease in the death rate from other causes of disease. Although the types of cancer that occur in first, second and third world countries varies, cancer remains one of the most important causes of death in all societies. 2 At the current time liver cancer is largely untreatable and more than 95% of patients will die due to the disease. 3 Sirtex Medical was formed to commercialise a portfolio of three technologies relating to the treatment of liver cancer. The Company has adapted techniques for targeting large numbers of micro-particles into tumours within the liver. These particles can be manufactured from a variety of materials and act as transport vehicles to carry anticancer agents such as ionising radiation, anti-cancer drugs or materials that can generate heat within the cancer. 4 The Company’s first product, SIR-Spheres ® is a micro-particle that can be rendered radioactive and can be targeted to tumours within liver tissue. Investment Highlights 5 SIR-Spheres ® have been evaluated in Phase II and Phase III clinical trials and more than 400 patients in Australia, New Zealand and Hong Kong have been treated. The Phase III clinical trial has demonstrated an increase in the remission times for patients receiving treatment. 6 General marketing approval for the sale of SIR-Spheres ® was granted in Australia by the Therapeutic Goods Administration in 1998. Regulatory approval has also been obtained for sale of SIR-Spheres ® in New Zealand, Hong Kong and Singapore. The Company is now pursuing registration in other relevant jurisdictions. In particular, the Company recently submitted a Pre-Market Approval Application to the Food & Drug Administration of the US Department of Health and Human Services for US marketing approval of SIR-Spheres ® . 7 Sirtex Medical’s second technology for the treatment of cancer involves the use of a patented matrix formulation to transport proven anticancer drugs to the site of the cancer. 8 The Company’s third technology for the treatment of cancer utilises the principle of targeted hyperthermia to treat cancer by raising the temperature of the tumour in order to destroy it. Sirtex Medical has developed a novel method for hyperthermia treatment of cancer using internally generated heat. 9 Sirtex Medical’s hyperthermia technology could develop into a new generic treatment platform for many types of cancer. 10 With the commercialisation of its technology Sirtex Medical aims to become a world leader in the treatment of cancer. 11 The Company expects the amount raised to fund the Company’s activities for a period of at least 3 years. The Company does not expect to need to raise any additional capital over this period. Sirtex Medical Prospectus 2000 3
Page 1 and 2: S I R T E X M E D I C A L L I M I T
Page 3: Chairman’s Letter Chairman’s Le
Page 7 and 8: Description of the Offer This Prosp
Page 9 and 10: • The extent of public and privat
Page 11 and 12: 4Section Industry Overview Sirtex M
Page 13 and 14: El-Serag and Mason (New England Jou
Page 15 and 16: 5Section Overview of Sirtex Medical
Page 17 and 18: Photograph of radioactive SIR-Spher
Page 19 and 20: Intellectual Property Position The
Page 21 and 22: Temp (c) 46 44 42 40 38 36 34 32 Th
Page 23 and 24: that has not been met with currentl
Page 25 and 26: 5.4.2 Costs of the Business The pro
Page 27 and 28: Manufacture of the SIR-Spheres will
Page 29 and 30: Board of Directors Dr Chris Roberts
Page 31 and 32: Section 7 Risk Factors 29
Page 33 and 34: Risk Factors Healthcare Funding Cha
Page 35 and 36: Section 8 Independent Accountants R
Page 37 and 38: Independent Accountants Report Duri
Page 39 and 40: Independent Accountants Report APPE
Page 41 and 42: Independent Accountants Report (e)
Page 43 and 44: Independent Accountants Report Cons
Page 45 and 46: Independent Accountants Report Cons
Page 47 and 48: Section 9 Reports on Patents 45
Page 49 and 50: Reports on Patents Patent Applicati
Page 51 and 52: Reports on Patents Date: 17 July 20
Page 53 and 54: Reports on Patents Patent Series 2
Page 55 and 56:
Reports on Patents Trade Mark Serie
Page 57 and 58:
Reports on Patents application unde
Page 59 and 60:
Section 10Additional Information 57
Page 61 and 62:
Additional Information attaching to
Page 63 and 64:
Additional Information Restricted s
Page 65 and 66:
Additional Information Material Con
Page 67 and 68:
Additional Information • approval
Page 69 and 70:
Additional Information Executive Se
Page 71 and 72:
Additional Information Consents and
Page 73 and 74:
Additional Information of a directo
Page 75 and 76:
Glossary of Terms and References Th
Page 77 and 78:
Glossary of Terms and References Bu
Page 79 and 80:
A B C E F Application Form SIRTEX M
Page 81 and 82:
A B C E F Application Form SIRTEX M
Page 83 and 84:
Design and Production: Downer Manci
show all

Sirtex Cover.proof 11 - School of Educators

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?